# Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement

> **NCT07090343** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Leiden University Medical Center** · enrollment: 826 (estimated)

## Conditions studied

- Aortic Stenosis
- Heart Failure

## Interventions

- **DRUG:** Wegovy ®
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07090343
- **Lead sponsor:** Leiden University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2030-09-01
- **Final completion:** 2031-04-01
- **Target enrollment:** 826 (ESTIMATED)
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07090343

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07090343, "Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07090343. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*